mTOR inhibitor therapy: Does it prevent HCC recurrence after liver transplantation?

Transplantation Reviews

Volumn 29, Issue 3, 2015, Pages 168-174

  Duvoux, Christophe ^a,b   Toso, Christian ^a,b  

^a HENRI MONDOR HOSPITAL   (France)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN; RAPAMYCIN; SORAFENIB; ANTINEOPLASTIC AGENT; MTOR PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE;

CANCER CHEMOTHERAPY; CANCER PREVENTION; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; DRUG EFFICACY; ENZYME INHIBITION; HUMAN; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; NONHUMAN; OVERALL SURVIVAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; REVIEW; SURVIVAL RATE; TREATMENT OUTCOME; TREATMENT PLANNING; ADVERSE EFFECTS; ANTAGONISTS AND INHIBITORS; CARCINOMA, HEPATOCELLULAR; COMPARATIVE STUDY; DRUG THERAPY; FEMALE; LIVER NEOPLASMS; MALE; PATHOLOGY; PREVENTION AND CONTROL; PROCEDURES; PROGNOSIS; RISK ASSESSMENT; TUMOR RECURRENCE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, HEPATOCELLULAR; EVEROLIMUS; FEMALE; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; SIROLIMUS; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME;

EID: 84937163990     PISSN: 0955470X     EISSN: 15579816     Source Type: Journal    
DOI: 10.1016/j.trre.2015.02.003     Document Type: Review

References (83)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
2. El-Serag H.B., Lau M., Eschbach K., Davila J., Goodwin J. Epidemiology of hepatocellular carcinoma in Hispanics in the United States. Arch Intern Med 2007, 167:1983-1989.
3. Sangiovanni A., Del Ninno E., Fasani P., et al. Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. Gastroenterology 2004, 126:1005-1014.
4. Llovet J.M., Burroughs A., Bruix J. Hepatocellular carcinoma. Lancet 2003, 362:1907-1917.
5. Frenette C., Gish R. Targeted systematic therapies for hepatocellular carcinoma: clinical perspectives, challenges and implications. World J Gastroenterol 2012, 18:498-506.
6. Mazzaferro V., Regalia E., Doci R., et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996, 334:693-699.
7. Yoo H.Y., Patt C.H., Geschwind J.F., Thuluvath P.J. The outcome of liver transplantation in patients with hepatocellular carcinoma in the United States between 1988 and 2001: 5-year survival has improved significantly with time. J Clin Oncol 2003, 21:4329-4335.
8. Clavien P.A., Lesurtel M., Bossuyt P.M., et al. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol 2012, 13:E11-E22.
9. Yao F.Y., Xiao L., Bass N.M., Kerlan R., Ascher N.L., Roberts J.P. Liver transplantation for hepatocellular carcinoma: validation of the UCSF expanded criteria based on preoperative imaging. Am J Transplant 2007, 7:2587-2596.
10. Zimmerman M.A., Trotter J.F., Wachs M., et al. Sirolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma. Liver Transpl 2008, 14:633-638.
11. Welker M.W., Bechstein W.O., Zeuzem S., Trojan J. Recurrent hepatocellular carcinoma after liver transplantation-an emerging clinical challenge. Transpl Int 2013, 26:109-118.
12. Llovet J.M., Ricci S., Mazzaferro V., et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008, 359:378-390.
13. Sposito C., Mariani L., Germini A., et al. Comparative efficacy of sorafenib versus best supportive care in recurrent hepatocellular carcinoma after liver transplantation: a case-control study. J Hepatol 2013, 59:59-66.
14. Duvoux C., Kiuchi T., Pestalozzi B., Busuttil R., Miksad R. What is the role of adjuvant therapy after liver transplantation for hepatocellular carcinoma?. Liver Transpl 2011, 17:S147-S158.
15. Roayaie S., Schwartz J.D., Sung M.W., et al. Recurrence of hepatocellular carcinoma after liver transplant: patterns and prognosis. Liver Transpl 2004, 10:534-540.
16. Yokoyama I., Carr B., Saitsu H., Iwatsuki S., Starzl T.E. Accelerated growth rates of recurrent hepatocellular carcinoma after liver transplantation. Cancer 1991, 68:2095-2100.
17. Cheng J.W., Shi Y.H., Fan J., et al. An immune function assay predicts post-transplant recurrence in patients with hepatocellular carcinoma. J Cancer Res Clin Oncol 2011, 137:1445-1453.
18. Decaens T., Roudot-Thoraval F., Bresson-Hadni S., et al. Role of immunosuppression and tumor differentiation in predicting recurrence after liver transplantation for hepatocellular carcinoma: a multicenter study of 412 patients. World J Gastroenterol 2006, 12:7319-7325.
19. Rodríguez-Perálvarez M., Tsochatzis E., Naveas M.C., et al. Reduced exposure to calcineurin inhibitors early after liver transplantation prevents recurrence of hepatocellular carcinoma. J Hepatol 2013, 59:1193-1199.
20. Vivarelli M., Cucchetti A., La Barba G., et al. Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence. Ann Surg 2008, 248:857-862.
21. Vivarelli M., Cucchetti A., Piscaglia F., et al. Analysis of risk factors for tumor recurrence after liver transplantation for hepatocellular carcinoma: key role of immunosuppression. Liver Transpl 2005, 11:497-503.
22. Sakai M., Miyake H., Tashiro S., Okumura Y., Kido H. Inhibitory effect of FK506 and cyclosporine A on the growth and invasion of human liver cancer cells. J Med Invest 2004, 51:63-69.
23. Freise C.E., Ferrell L., Liu T., Ascher N.L., Roberts J.P. Effect of systemic cyclosporine on tumor recurrence after liver transplantation in a model of hepatocellular carcinoma. Transplantation 1999, 67:510-513.
24. Daoudaki M., Fouzas I., Stapf V., et al. Cyclosporine a augments P-glycoprotein expression in the regenerating rat liver. Biol Pharm Bull 2003, 26:303-307.
25. Ceriello A., Mezza F., Cozzolino S., et al. Role of immunosuppression in recurrence after liver transplantation for diethylnitrosamine-induced tumors in rats. Transpl Int 1994, 7:S204-S207.
26. Porta C., Paglino C., Mosca A. Targeting PI3K/Akt/mTOR signaling in cancer. Front Oncol 2014, 4:1-11. Art 64.
27. Motzer R.J., Escudier B., Oudard S., et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008, 372:449-456.
28. André F., O'Regan R., Ozguroglu M., et al. Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol 2014, 15:580-591.
29. Maass N., Harbeck N., Mundhenke C., et al. Everolimus as treatment for breast cancer patients with bone metastases only: results of the phase II RADAR study. J Cancer Res Clin Oncol 2013, 139:2047-2056.
30. Bachelot T., Bourgier C., Cropet C., et al. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J Clin Oncol 2012, 30:2718-2724.
31. Bissler J.J., Kingswood J.C., Radzikowska E., et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 2013, 381:817-824.
32. Franz D.N., Belousova E., Sparagana S., et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 2013, 381:125-132.
33. Pavel M.E., Hainsworth J.D., Baudin E., et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet 2011, 378:2005-2012.
34. Campbell S.B., Walker R., Tai S.S., Jiang Q., Russ G.R. Randomized controlled trial of sirolimus for renal transplant recipients at high risk for nonmelanoma skin cancer. Am J Transplant 2012, 12:1146-1156.
35. Euvrard S., Morelon E., Rostaing L., et al. Sirolimus and secondary skin-cancer prevention in kidney transplantation. N Engl J Med 2012, 367:329-339.
36. Zhu A.X., Abrams T.A., Miksad R., et al. Phase 1/2 study of everolimus in advanced hepatocellular carcinoma. Cancer 2011, 117:5094-5102.
37. Sahin F., Kannangai R., Adegbola O., Wang J., Su G., Torbenson M. mTOR and P70 S6 kinase expression in primary liver neoplasms. Clin Cancer Res 2004, 10:8421-8425.
38. Bjornsti M.A., Houghton P.J. The TOR pathway: a target for cancer therapy. Nat Rev Cancer 2004, 4:335-348.
39. Villaneuva A., Chiang D.Y., Newell P., et al. Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology 2008, 135:1972-1983.
40. Sieghart W., Fuereder T., Schmid K., et al. Mammalian target of rapamycin pathway activity in hepatocellular carcinomas of patients undergoing liver transplantation. Transplantation 2007, 83:425-432.
41. Matter M.S., Decaens T., Andersen J.B., Thorgeirsson S.S. Targeting the mTOR pathway in hepatocellular carcinoma: current state and future trends. J Hepatol 2014, 60:855-865.
42. Piguet A.C., Majumder S., Maheshwari U., et al. Everolimus is a potent inhibitor of activated hepatic stellate cell functions in vitro and in vivo, while demonstrating anti-angiogenic activities. Clin Sci (Lond) 2014, 126:775-784.
43. Semela D., Piguet A.C., Kolev M., et al. Vascular remodeling and antitumoral effects of mTOR inhibition in a rat model of hepatocellular carcinoma. J Hepatol 2007, 46:840-848.
44. Huynh H., Chow K.H., Soo K.C., et al. RAD001 (everolimus) inhibits tumour growth in xenograft models of human hepatocellular carcinoma. J Cell Mol Med 2009, 13:1371-1380.
45. Piguet A.C., Saar B., Hlushchuk R., et al. Everolimus augments the effects of sorafenib in a syngeneic orthotopic model of hepatocellular carcinoma. Mol Cancer Ther 2011, 10:1007-1017.
46. Thomas H.E., Mercer C.A., Carnevalli L.S., et al. mTOR inhibitors synergize on regression, reversal of gene expression, and autophagy in hepatocellular carcinoma. Sci Transl Med 2012, 4:1-12. 139ra84.
47. Chan S.L., Wong C.H., Lau C.P., et al. Preclinical evaluation of combined TKI-258 and RAD001 in hepatocellular carcinoma. Cancer Chemother Pharmacol 2013, 71:1417-1425.
48. Piguet A.C., Semela D., Keogh A., et al. Inhibition of mTOR in combination with doxorubicin in an experimental model of hepatocellular carcinoma. J Hepatol 2008, 49:78-87.
49. Guba M., von Breitenbuch P., Steinbauer M., et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002, 8:128-135.
50. Luan F.L., Hojo M., Maluccio M., Yamaji K., Suthanthiran M. Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy. Transplantation 2002, 73:1565-1572.
51. Koehl G.E., Andrassy J., Guba M., et al. Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice. Transplantation 2004, 77:1319-1326.
52. Decaens T., Luciani A., Itti E., et al. Phase II study of sirolimus in treatment-naive patients with advanced hepatocellular carcinoma. Dig Liver Dis 2012, 44:610-616.
53. Rizell M., Andersson M., Cahlin C., Hafström L., Olausson M., Lindnér P. Effects of the mTOR inhibitor sirolimus in patients with hepatocellular and cholangiocellular cancer. Int J Clin Oncol 2008, 13:66-70.
54. Zhu A.X., Kudo M., Assenat E., et al. Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial. JAMA 2014, 312:57-67.
55. De Simone P., Crocetti L., Pezzati D., et al. Efficacy and safety of combination therapy with everolimus and sorafenib for recurrence of hepatocellular carcinoma after liver transplantation. Transplant Proc 2014, 46:241-244.
56. Gomez-Martin C., Bustamante J., Castroagudin J.F., et al. Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation. Liver Transpl 2012, 18:45-52.
57. Shiah H.S., Chen C.Y., Dai C.Y., et al. Randomised clinical trial: comparison of two everolimus dosing schedules in patients with advanced hepatocellular carcinoma. Aliment Pharmacol Ther 2013, 37:62-73.
58. Finn R.S. Advanced HCC: emerging molecular therapies. Minerva Gastroenterol Dietol 2012, 58:25-34.
59. Yamanaka K., Petrulionis M., Lin S., et al. Therapeutic potential and adverse events of everolimus for treatment of hepatocellular carcinoma-systematic review and meta-analysis. Cancer Med 2013, 2:862-871.
60. Gomez-Camarero J., Salcedo M., Rincon D., et al. Use of everolimus as a rescue immunosuppressive therapy in liver transplant patients with neoplasm. Transplantation 2007, 84:786-791.
61. Bilbao I., Dopazo C., Lazaro J., et al. Multiple indications for everolimus after liver transplantation in current clinical practice. World J Transplant 2014, 4:122-132.
62. Elsharkawi M., Staib L., Henne-Bruns D., Mayer J. Complete remission of posttransplant lung metastases from hepatocellular carcinoma under therapy with sirolimus and mycophenolate mofetil. Transplantation 2005, 79:855-857.
63. Valdivieso A., Bustamante J., Gastaca M., et al. Management of hepatocellular carcinoma recurrence after liver transplantation. Transplant Proc 2010, 42:660-662.
64. Mártinez J.M., Pulido L.B., Bellido C.B., et al. Rescue immunosuppression with mammalian target of rapamycin inhibitor drugs in liver transplantation. Transplant Proc 2010, 42:641-643.
65. Bhoori S., Toffanin S., Sposito C., et al. Personalized molecular targeted therapy in advanced, recurrent hepatocellular carcinoma after liver transplantation: a proof of principle. J Hepatol 2010, 52:771-775.
66. Schnitzbauer A.A., Zuelke C., Graeb C., et al. A prospective randomized, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma. BMC Cancer 2010, 10:1-8. 190.
67. Zhou J., Wang Z., Wu Z.Q., et al. Sirolimus-based immunosuppression therapy in liver transplantation for patients with hepatocellular carcinoma exceeding the Milan criteria. Transplant Proc 2008, 40:3548-3553.
68. Houssel P., Latournerie M., Jezequel E., et al. Everolimus in liver transplantation to prevent hepatocellular carcinoma recurrence in the presence of extended Milan criteria. J Hepatol 2013, 58:S72.
69. Vivarelli M., Dazzi A., Zanello M., et al. Effect of different immunosuppressive schedules on recurrence-free survival after liver transplantation for hepatocellular carcinoma. Transplantation 2010, 89:227-231.
70. Nocera A., Andorno E., Tagliamacco A., et al. Sirolimus therapy in liver transplant patients: an initial experience at a single center. Transplant Proc 2008, 40:1950-1952.
71. Chen Y.B., Sun Y.A., Gong J.P. Effects of rapamycin in liver transplantation. Hepatobiliary Pancreat Dis Int 2008, 7:25-28.
72. Cinnakotla S., Davis G.L., Vasani S., et al. Impact of sirolimus on the recurrence of hepatocellular carcinoma after liver transplantation. Liver Transplant 2009, 15:1834-1842.
73. Toso C., Merani S., Bigam D.L., Shapiro A.M., Kneteman N.M. Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma. Hepatology 2010, 51:1237-1243.
74. Menon K.V., Hakeem A.R., Heaton N.D. Meta-analysis: recurrence and survival following the use of sirolimus in liver transplantation for hepatocellular carcinoma. Aliment Pharmacol Ther 2013, 37:411-419.
75. Liang W., Wang D., Ling X., et al. Sirolimus-based immunosuppression in liver transplantation for hepatocellular carcinoma: a meta-analysis. Liver Transpl 2012, 18:62-69.
76. Masetti M., Montalti R., Rompianesi G., et al. Early withdrawal of calcineurin inhibitors and everolimus monotherapy in de novo liver transplant patients preserves renal function. Am J Transplant 2010, 10:2252-2262.
77. De Simone P., Nevens F., De Carlis L., et al. Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trial. Am J Transplant 2012, 12:3008-3020.
78. Fischer L., Saliba F., Kaiser G.M., et al. Three-year outcomes in de novo liver transplant patients receiving everolimus with reduced tacrolimus: Follow-up results from a randomized, multicenter study. Transplantation 2014, [in press].
79. Fischer L., Klempnauer J., Beckebaum S., et al. A randomized, controlled study to assess the conversion from calcineurin-inhibitors to everolimus after liver transplantation-PROTECT. Am J Transplant 2012, 12:1855-1865.
80. Perrakis A., Schwarz K., Yedibela S., Croner R.S., Hohenberger W., Müller V. Impact of the conversion of the immunosuppressive regimen from Prograf to Advagraf or to sirolimus in long-term stable liver transplant recipients: indications, safety, and outcome. Transplant Proc 2011, 43:3702-3707.
81. Watt K.D., Dierkhising R., Heimbach J.K., Charlton M.R. Impact of sirolimus and tacrolimus on mortality and graft loss in liver transplant recipients with or without hepatitis C virus: an analysis of the Scientific Registry of Transplant Recipients database. Liver Transpl 2012, 18:1029-1036.
82. Junge G., Saliba F., De Simone P., et al. Everolimus impact on hepatocellular carcinoma recurrence after liver transplantation-12, 24, and 36months data from 719 LTx recipients. Am Transplant 2014, 14:694. [Abstract A376].
83. Toso C., Mentha G., Majno P. Integrating sorafenib into an algorithm for the management of post-transplant hepatocellular carcinoma recurrence. J Hepatol 2013, 59:3-5.3.